Research Area:	Clinical Epidemiology

Jane Green is a clinical epidemiologist working primarily on the Million Women Study and on studies related to cancer screening; she also holds a Research Lectureship at the University of Oxford. Before joining the Unit in 1997, Jane worked in clinical medicine in the Oxford region.

Within the Million Women Study, Jane is responsible for the collection of blood samples for genetic analyses, and is working on analyses of data on hormone replacement therapy and other environmental risk factors in relation to gastrointestinal and other cancers. She is also carrying out related analyses of risk factors for gastrointestinal cancers using the General Practice Research Database.

Jane is lead epidemiologist for the Cancer Screening Programmes Research Unit and is currently working on a study of factors related to testing false positive in the NHS Bowel Cancer Screening Programme. She also contributes to the Unit's international collaborative studies of hormonal factors in cancer.

She is Associate Editor (cancer screening and epidemiology) for Cancer Epidemiology, and a member of the Editorial Board of the British Journal of Cancer.

There are no collaborations listed for this principal investigator.

Reeves GK, Travis RC, Green J, Bull D, Tipper S, Baker K, Beral V, Peto R, Bell J, Zelenika D, Lathrop M, Million Women Study Collaborators et al. 2010. Incidence of breast cancer and its subtypes in relation to individual and multiple low-penetrance genetic susceptibility loci. JAMA, 304 (4), pp. 426-434. Read abstract | Read more

There is limited evidence on how the risk of breast cancer and its subtypes depend on low-penetrance susceptibility loci, individually or in combination. Hide abstract

Travis RC, Reeves GK, Green J, Bull D, Tipper SJ, Baker K, Beral V, Peto R, Bell J, Zelenika D, Lathrop M, Million Women Study Collaborators et al. 2010. Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study. Lancet, 375 (9732), pp. 2143-2151. Read abstract | Read more

Information is scarce about the combined effects on breast cancer incidence of low-penetrance genetic susceptibility polymorphisms and environmental factors (reproductive, behavioural, and anthropometric risk factors for breast cancer). To test for evidence of gene-environment interactions, we compared genotypic relative risks for breast cancer across the other risk factors in a large UK prospective study. Hide abstract

Benson VS, Pirie K, Green J, Bull D, Casabonne D, Reeves GK, Beral V, Million Women Study Collaborators. 2010. Hormone replacement therapy and incidence of central nervous system tumours in the Million Women Study. Int J Cancer, 127 (7), pp. 1692-1698. Read abstract | Read more

We examined the relation between the use of hormone replacement therapy (HRT) and the incidence of central nervous system (CNS) tumours in a large prospective study of 1,147,894 postmenopausal women. Women were aged 56.6 years on average at entry, and HRT use was recorded at recruitment and updated, where possible, about 3 years later. During a mean follow-up of 5.3 years per woman, 1,266 CNS tumours were diagnosed, including 557 gliomas, 311 meningiomas and 117 acoustic neuromas. Compared with never users of HRT, the relative risks (RRs) for all incident CNS tumours, gliomas, meningiomas and acoustic neuromas in current users of HRT were 1.20 (95% CI: 1.05-1.36), 1.09 (95% CI: 0.89-1.32), 1.34 (95% CI: 1.03-1.75) and 1.58 (95% CI: 1.02-2.45), respectively, and there was no significant difference in the relative risks by tumour type (heterogeneity p = 0.2). In past users of HRT the relative risk was 1.07 (95% CI: 0.93-1.24) for all CNS tumours. Among current users of HRT, there was significant heterogeneity by the type of HRT with the users of oestrogen-only HRT at higher risk of all CNS tumours than users of oestrogen-progestagen HRT (RR = 1.42, 95% CI: 1.21-1.67 versus RR = 0.97, 95% CI: 0.82-1.16) (heterogeneity p < 0.001). Among current users of oestrogen-only and oestrogen-progestagen HRT, there was no significant heterogeneity by duration of use, hormonal constituent or mode of administration of HRT. Hide abstract

Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. 2010. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ, 341 pp. c4444. Read abstract | Read more

To examine the hypothesis that risk of oesophageal, but not of gastric or colorectal, cancer is increased in users of oral bisphosphonates. Hide abstract

Sweetland S, Green J, Liu B, Berrington de González A, Canonico M, Reeves G, Beral V, Million Women Study collaborators. 2009. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ, 339 pp. b4583. Read abstract

To examine the duration and magnitude of increased risk of venous thromboembolism after different types of surgery. Hide abstract

International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodhill A, Green J, Peto J, Plummer M, Sweetland S. 2007. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet, 370 (9599), pp. 1609-1621. Read abstract | Read more

Combined oral contraceptives are classified by the International Agency for Research on Cancer as a cause of cervical cancer. As the incidence of cervical cancer increases with age, the public-health implications of this association depend largely on the persistence of effects long after use of oral contraceptives has ceased. Information from 24 studies worldwide is pooled here to investigate the association between cervical carcinoma and pattern of oral contraceptive use. Hide abstract

Watson J, Wise L, Green J. 2007. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol, 63 (9), pp. 843-849. Read abstract | Read more

The purpose of this study was to examine recent trends in the prescribing of hormone therapy for menopause, tibolone, and bisphosphonate preparations for the prevention or treatment of osteoporosis, in the UK in relation to publication of research evidence on the health effects of hormone therapy and subsequent changes in prescribing advice. Hide abstract

Beral V, Million Women Study Collaborators, Bull D, Green J, Reeves G. 2007. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet, 369 (9574), pp. 1703-1710. Read abstract | Read more

Ovarian cancer is the fourth most common cancer in women in the UK, with about 6700 developing the malignancy and 4600 dying from it every year. However, there is limited information about the risk of ovarian cancer associated with the use of hormone replacement therapy (HRT). Hide abstract